Xilio Therapeutics Inc (XLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2023 | 06-2023 | 03-2023 | 12-2022 | 09-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -58,749 | -42,001 | -22,646 | -88,222 | -65,756 |
| Depreciation Amortization | 1,451 | 991 | 499 | 1,847 | 1,358 |
| Accounts payable and accrued liabilities | -1,625 | -2,167 | -1,358 | 485 | -972 |
| Other Working Capital | -2,894 | -5,594 | -5,331 | 1,660 | -1,159 |
| Other Operating Activity | 6,624 | 6,947 | 3,586 | 8,507 | 9,029 |
| Operating Cash Flow | $-55,193 | $-41,824 | $-25,250 | $-75,723 | $-57,500 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -486 | -486 | -170 | -1,867 | -1,358 |
| Investing Cash Flow | $-486 | $-486 | $-170 | $-1,867 | $-1,358 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -5,064 | -2,820 | -1,688 | -85 | -64 |
| Common Stock Issued | 148 | 140 | N/A | 16 | 16 |
| Financing Cash Flow | $-4,916 | $-2,680 | $-1,688 | $-69 | $-48 |
| Beginning Cash Position | 121,947 | 121,947 | 121,947 | 199,606 | 199,606 |
| End Cash Position | 61,352 | 76,957 | 94,839 | 121,947 | 140,700 |
| Net Cash Flow | $-60,595 | $-44,990 | $-27,108 | $-77,659 | $-58,906 |
| Free Cash Flow | |||||
| Operating Cash Flow | -55,193 | -41,824 | -25,250 | -75,723 | -57,500 |
| Capital Expenditure | -486 | -486 | -170 | -1,867 | -1,358 |
| Free Cash Flow | -55,679 | -42,310 | -25,420 | -77,590 | -58,858 |